Description: Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Home Page: marinuspharma.com
MRNS Technical Analysis
5 Radnor Corporate Center
Radnor,
PA
19087
United States
Phone:
484 801 4670
Officers
| Name | Title |
|---|---|
| Dr. Scott N. Braunstein M.D. | CEO, Pres & Chairman |
| Mr. Steven E. Pfanstiel C.M.A., M.B.A. | CFO & Treasurer |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
| Ms. Sasha Damouni Ellis | VP of Corp. Affairs & Investor Relations |
| Ms. Martha E. Manning | VP, Gen. Counsel & Sec. |
| Mr. Thomas J. Lyons | Sr. VP of Corp., Bus. Devel. & Commercial Planning |
| Ms. Lisa Lejuwaan | VP of Sales |
| Ms. Sonya Weigle | VP of HR |
| Dr. Kimberly A. McCormick Pharm.D., PharmD | Sr. VP and Head of Regulatory Affairs & Quality Assurance |
| Dr. Alex Aimetti Ph.D. | Sr. VP of Scientific Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.654 |
| Price-to-Sales TTM: | 10.2057 |
| IPO Date: | 2014-07-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 113 |